Druggable genome and precision medicine in cancer: current challenges.

Dupont, Camille Amandine; Riegel, Kristina; Pompaiah, Malvika; Juhl, Hartmut; Rajalingam, Krishnaraj

Dupont, Camille Amandine; Riegel, Kristina; Pompaiah, Malvika; Juhl, Hartmut; Rajalingam, Krishnaraj.

Afiliação

Dupont CA; Cell Biology Unit, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Riegel K; Cell Biology Unit, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Pompaiah M; Cell Biology Unit, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Juhl H; Indivumed GmbH, Hamburg, Germany.
Rajalingam K; Indivumed-IMCB joint lab, IMCB, A*Star, Singapore.

FEBS J ; 288(21): 6142-6158, 2021 11.

Article em En | MEDLINE | ID: mdl-33626231

Assuntos

Genoma Humano/genética; Medicina de Precisão/métodos; Resistencia a Medicamentos Antineoplásicos/genética; Humanos; Organoides/metabolismo

Palavras-chave

biobanking; drug resistance; druggable genome; oncogenes; organoids; personalized therapeutics; precision medicine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Genoma Humano / Medicina de Precisão Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google